CD274 and head and neck squamous cell carcinoma: Preliminary results from the safety run-in phase of the phase II BNT111-01 trial, studying BNT113 plus pembrolizumab as a first-line treatment for recurrent/metastatic HPV-16-positive, PD-L1-positive (CPS ≥ 1) HNSCC have been reported.